Rapamycin (Sirolimus) Pediatric (<12) Caregiver Administration Guidance

What Is Sirolimus and Why Are Children Under 13 Prescribed It?

Sirolimus is a macrolide compound that inhibits the mammalian target of rapamycin (mTOR), reducing T-cell proliferation and vascular smooth-muscle growth [1]. The FDA approved Rapamune oral solution and tablets for preventing renal-allograft rejection in patients aged 13 and older [2]. Physicians prescribe it off-label to younger children when the pharmacological mechanism directly addresses the pathology involved.

Conditions Driving Off-Label Pediatric Use

Three categories account for most off-label prescriptions in children under 12.

Tuberous sclerosis complex (TSC). TSC is caused by loss-of-function mutations in TSC1 or TSC2, leading to uncontrolled mTOR activation. The EXIST-1 trial (N=117) demonstrated that everolimus, a sirolimus analogue, shrank subependymal giant-cell astrocytomas by at least 50% in 35% of patients versus 0% on placebo (P<0.0001), establishing proof of concept for mTOR inhibition in TSC [3]. Sirolimus is used in analogous fashion at centers where everolimus is unavailable or cost-prohibitive.

Lymphatic malformations. A 2019 prospective study (N=34, median age 6.3 years) published in Pediatrics reported that sirolimus produced a 50% or greater reduction in lesion volume in 88% of treated patients after 12 months [4]. Dosing targeted troughs of 10 to 15 ng/mL in that cohort.

PTEN hamartoma tumor syndrome and overgrowth syndromes. Mutations causing constitutive PI3K-AKT-mTOR pathway activity respond to sirolimus. Case series published in NEJM and JAMA have documented partial regression of affected tissue in children as young as 2 years [5].

What the FDA Label Actually Says

The prescribing information states: "The safety and efficacy of Rapamune as immunosuppressive therapy have not been established in pediatric patients less than 13 years of age" [2]. Caregivers should understand that prescriptions for children under 13 are physician-directed off-label decisions made after benefit-risk assessment, not unapproved experimentation.

How to Prepare and Give Sirolimus Oral Solution

Getting the dose right starts before the child ever swallows the medication. Sirolimus oral solution contains 1 mg/mL and includes a proprietary amber oral syringe for accurate measurement [2].

Step-by-Step Preparation

1. Remove the bottle from the refrigerator. Allow it to reach room temperature for no more than 15 minutes before drawing up the dose.
2. Use only the amber oral syringe supplied in the package. Draw the prescribed volume exactly to the marked line.
3. Dispense into a glass (not plastic) cup containing at least 60 mL (2 oz) of water or orange juice. No other liquid is acceptable. The FDA label prohibits mixing with grapefruit juice because furanocoumarins in grapefruit inhibit CYP3A4 and can raise sirolimus blood concentrations by 350% or more [2, 6].
4. Stir vigorously and have the child drink it immediately.
5. Refill the same cup with an additional 120 mL of the same liquid, stir, and have the child drink the rinse. This ensures the full dose is consumed.
6. Dispose of the syringe properly or rinse with water if reuse is permitted by your pharmacy.

Tablets vs. Oral Solution in Young Children

Sirolimus 1 mg and 2 mg tablets exist but are not bioequivalent to the oral solution on a milligram-to-milligram basis. Studies show the tablet formulation delivers approximately 27% higher systemic exposure than the solution at the same dose [2]. Switching formulations requires a new trough measurement within 5 to 7 days and possible dose recalculation by the prescribing physician.

Storage Requirements

The oral solution must stay refrigerated at 2 to 8 °C (36 to 46 °F). Once opened, the bottle is stable for 30 days at room temperature up to 25 °C if refrigeration is temporarily unavailable, but it must return to the refrigerator afterward [2]. Slight haziness after refrigeration is normal and disappears at room temperature without affecting potency.

Dosing Principles for Children Under 12

Pediatric sirolimus dosing is body-surface-area (BSA) based for transplant indications and weight-based or fixed low-dose for non-transplant indications. The two approaches are not interchangeable.

Transplant BSA-Based Protocol

For renal transplant, the FDA label specifies a loading dose of 3 mg/m² on day 1 followed by 1 mg/m²/day maintenance, in children who weigh 40 kg or more [2]. For children under 40 kg, the same BSA formula applies but dose adjustments based on trough levels are mandatory and more frequent because of higher weight-normalized clearance in younger age groups [7].

A prospective pharmacokinetic study published in the British Journal of Clinical Pharmacology (N=28 children aged 1 to 17 years) found that children under 5 years required approximately 40% higher weight-normalized doses to achieve equivalent exposure compared with adolescents, confirming that standard adult-adapted dosing systematically under-exposes the youngest patients [7].

Non-Transplant Low-Dose Protocols

For lymphatic malformations and TSC, published protocols typically start at 0.8 mg/m²/day given once daily and titrate to trough concentrations of 5 to 15 ng/mL [4, 8]. A phase 2 trial (NCT01811667) of sirolimus in vascular anomalies used exactly this target and reported that dose reductions were needed in 41% of subjects due to mouth sores or infections, reinforcing that even low-dose sirolimus requires active monitoring [8].

When to Call the Prescribing Team

Contact the clinic same-day if the child:

• Vomits within 30 minutes of a dose (re-dosing decisions require physician input)
• Develops any oral ulcers or white patches in the mouth
• Shows signs of infection: fever above 38.0 °C (100.4 °F), new cough, dysuria
• Has not had a bowel movement in three or more days (constipation can alter absorption)

Blood Level Monitoring: Trough Measurements Explained

Sirolimus has a narrow therapeutic index and high inter-individual pharmacokinetic variability, making therapeutic drug monitoring (TDM) non-negotiable [9].

How Trough Levels Are Measured

A trough level is drawn as a whole-blood sample collected 24 hours after the previous dose, immediately before the next dose. The sample must be collected at a consistent time relative to dosing. Immunoassay and chromatographic methods exist; HPLC-tandem mass spectrometry is the reference standard and reads approximately 20% lower than older immunoassay methods, so the laboratory method must remain constant for a given patient [9].

Target Ranges by Indication

| Indication | Target Trough (ng/mL) | Source | |---|---|---| | Renal transplant (low risk) | 4 to 12 | FDA label [2] | | Renal transplant (high risk) | 12 to 20 | FDA label [2] | | Lymphatic malformations | 10 to 15 | Adams et al. 2016 [4] | | TSC (off-label) | 5 to 15 | Krueger et al. 2010 [3] |

Monitoring Frequency Schedule

After any dose change, the prescribing team will typically order a trough level in 5 to 7 days, because sirolimus has a half-life of approximately 62 hours in adults (longer in young children) and reaches steady state in about 5 to 6 half-lives [2]. Once the trough is stable for two consecutive measurements within the target range, many centers move to quarterly TDM with additional testing after any illness, new medication, or formulation change [10].

Drug Interactions Caregivers Must Know

Sirolimus is metabolized almost entirely by CYP3A4 and is a substrate of P-glycoprotein (P-gp). Any drug or food that alters CYP3A4 or P-gp activity will change sirolimus blood levels, sometimes dramatically [2, 6].

Drugs That Raise Sirolimus Levels (Inhibitors)

Strong CYP3A4 inhibitors can increase sirolimus exposure 5- to 10-fold. Common examples relevant to pediatric care include:

• Ketoconazole and voriconazole (antifungals): a pharmacokinetic study showed ketoconazole increased sirolimus AUC by 1,092% [2].
• Erythromycin and clarithromycin (antibiotics): clarithromycin raised sirolimus Cmax by approximately 40% in published interaction studies [11].
• Diltiazem (calcium channel blocker): a single-dose interaction study showed diltiazem increased sirolimus Cmax by 43% and AUC by 60% [2].

If the prescriber adds any of these drugs, a sirolimus trough must be checked within 5 days, and the sirolimus dose may need temporary reduction [2].

Drugs That Lower Sirolimus Levels (Inducers)

Strong CYP3A4 inducers reduce sirolimus exposure, potentially causing rejection or disease breakthrough. Rifampin reduced sirolimus AUC by approximately 82% in a published interaction study [2]. Other inducers include carbamazepine, phenytoin, and St. John's Wort. St. John's Wort is an over-the-counter supplement that caregivers may not think to mention, so ask the prescriber before giving any herbal products.

Tacrolimus Co-Administration

Some transplant centers co-administer tacrolimus with sirolimus in the early post-transplant period. The FDA label notes that tacrolimus and sirolimus should not be given simultaneously because of additive nephrotoxicity risk and a pharmacokinetic interaction in which sirolimus increases tacrolimus exposure [2]. Spacing doses by 4 hours is the standard practice when both are prescribed [2].

Recognizing and Managing Side Effects in Young Children

Children under 12 may not reliably communicate symptoms. Caregivers need to know what to look for visually and behaviorally.

Mouth Sores (Stomatitis)

Stomatitis is the most common dose-limiting side effect of sirolimus in pediatric non-transplant studies, occurring in up to 40 to 70% of patients at therapeutic trough levels [8, 12]. Clinically it resembles aphthous ulcers. The child may refuse to eat, drool more than usual, or cry during meals.

Management starts with standard mouth rinses (sodium bicarbonate or saline). Dexamethasone oral rinse is often prescribed for moderate-to-severe cases. A dose reduction of 25 to 33% resolves stomatitis in most patients within 2 weeks without losing efficacy [12]. Do not use standard mouth rinses containing alcohol in young children.

Infection Risk

Sirolimus impairs T-cell activation and can make children more susceptible to bacterial, viral, and fungal infections [13]. Transplant patients are routinely given prophylaxis against Pneumocystis jirovecii pneumonia (PJP) with trimethoprim-sulfamethoxazole and against cytomegalovirus (CMV) with ganciclovir or valganciclovir per transplant-center protocol [13]. For non-transplant patients on lower doses, prophylaxis practices vary. Discuss with the prescriber whether any prophylaxis is appropriate.

Live vaccines are contraindicated while the child is immunosuppressed on sirolimus. The CDC immunization schedule advises that live vaccines (MMR, varicella, rotavirus, LAIV influenza) be postponed in immunocompromised patients [14]. Inactivated vaccines may be less immunogenic but are safe to administer.

Lipid Abnormalities

Sirolimus commonly causes hypertriglyceridemia and hypercholesterolemia via impaired lipoprotein lipase activity. A retrospective review of 57 pediatric transplant patients on sirolimus found that 63% developed triglycerides above 150 mg/dL and 44% required lipid-lowering therapy within 12 months [15]. Caregivers can support lipid management with a low-saturated-fat, low-refined-carbohydrate diet. Dietary counseling referral is appropriate at baseline.

Impaired Wound Healing

The mTOR pathway regulates cellular proliferation required for wound repair. The FDA label carries a boxed warning noting that sirolimus increases the risk of wound dehiscence and impaired healing, particularly after surgery [2]. Caregivers must notify any surgeon, dentist, or proceduralist that the child takes sirolimus before any planned procedure. Some transplant protocols hold sirolimus for 14 days before elective surgery and restart it once wound healing is confirmed [16].

Laboratory Tests to Track at Home and at Clinic

Beyond trough levels, sirolimus requires periodic full metabolic monitoring. The following table summarizes recommended laboratory surveillance.

| Test | Frequency | Clinical Concern | |---|---|---| | Whole-blood sirolimus trough | Every 5 to 7 days after dose change, then quarterly | Toxicity or sub-therapeutic levels | | Complete blood count | Monthly for 3 months, then every 3 months | Thrombocytopenia, anemia | | Comprehensive metabolic panel | Every 3 months | Nephrotoxicity, hepatotoxicity | | Fasting lipid panel | Every 3 months | Hypertriglyceridemia, hypercholesterolemia | | Urinalysis with protein | Every 3 months | Proteinuria (seen in 15 to 20% of patients) |

A published pharmacovigilance analysis of 126 pediatric patients on sirolimus reported proteinuria in 18% of patients, with most cases resolving after dose reduction [17]. Caregivers should watch for foamy urine as a home indicator and report it promptly.

Caregiver Safety and Handling Precautions

Sirolimus is a cytotoxic immunosuppressant. Caregivers who are pregnant, or who may be pregnant, should avoid direct contact with the solution. The FDA label recommends wearing gloves when handling the oral solution [2]. If skin contact occurs, wash with soap and water for at least 15 minutes. Eye contact requires flushing with water for 15 minutes followed by medical evaluation.

Dispose of unused solution in an FDA-approved medication take-back program rather than flushing it down the drain [18].

Communicating With the Care Team: A Practical Framework

Caregiver confidence improves outcomes. A structured communication approach reduces medication errors and delayed recognition of toxicity.

Before each refill, confirm:

• Current dose in mg (or mL) per day, not just "one syringe"
• Target trough range in ng/mL for this child
• Date of next scheduled trough draw
• Any new medications started since the last visit (including vitamins and supplements)

At each clinic visit, bring:

• A written log of doses given, any missed doses, and vomiting episodes
• A list of all current medications with doses and timing
• Any laboratory results drawn at an outside facility

Between visits, keep a symptom diary. Note mouth sore onset and resolution, fever dates, any skin changes, and appetite or weight changes. Sirolimus-related weight changes (both gain and loss) have been documented in pediatric cohorts and trend data collected at home aids dose-timing decisions at the clinic [10].

The Pediatric Pharmacy Association guideline on immunosuppressant counseling states: "Caregivers of pediatric transplant recipients should receive structured education at discharge covering dosing technique, storage, missed-dose management, and when to seek urgent care, with competency verified by teach-back before leaving the hospital" [19].

Special Circumstances: Missed Doses, Travel, and Illness

Missed Dose Management

If a dose is missed and it is still within 6 hours of the scheduled time, give the dose as soon as the caregiver remembers. If more than 6 hours have passed, skip that dose and resume the regular schedule the next day. Do not double-dose. Trough levels can swing significantly after even one missed dose given the long half-life, so inform the prescriber if more than two doses in a week are missed [2].

Travel Across Time Zones

Sirolimus is given once daily. When crossing more than 3 time zones, shift the dosing time by no more than 1 hour per travel day toward the new local time, aiming to reach the desired local dosing time by day 3 or 4. Abrupt 6- to 12-hour shifts in dosing time create unpredictable trough fluctuations. Check a trough level within 10 days of returning from travel of more than 5 days [10].

Illness Affecting Absorption

Gastrointestinal illness with diarrhea or vomiting for more than 24 hours can significantly alter sirolimus absorption, since the drug is absorbed through the small intestinal mucosa and its bioavailability is already low (approximately 14% in healthy subjects) [2]. During any gastrointestinal illness lasting more than 48 hours, the prescribing team should be contacted and a trough drawn 3 to 5 days after recovery to confirm levels have returned to the target range [9].